ZA200204710B - Gene therapy of HIV-positive patients by the expression of membrane-achored GP41 peptides. - Google Patents

Gene therapy of HIV-positive patients by the expression of membrane-achored GP41 peptides.

Info

Publication number
ZA200204710B
ZA200204710B ZA200204710A ZA200204710A ZA200204710B ZA 200204710 B ZA200204710 B ZA 200204710B ZA 200204710 A ZA200204710 A ZA 200204710A ZA 200204710 A ZA200204710 A ZA 200204710A ZA 200204710 B ZA200204710 B ZA 200204710B
Authority
ZA
South Africa
Prior art keywords
membrane
hiv
peptides
expression
achored
Prior art date
Application number
ZA200204710A
Other languages
English (en)
Inventor
Meike-Dorothee Von Laer
Original Assignee
Pette Heinrich Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pette Heinrich Inst filed Critical Pette Heinrich Inst
Publication of ZA200204710B publication Critical patent/ZA200204710B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
ZA200204710A 1999-11-25 2002-06-12 Gene therapy of HIV-positive patients by the expression of membrane-achored GP41 peptides. ZA200204710B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19957838A DE19957838C2 (de) 1999-11-25 1999-11-25 Gentherapie von HIV-Infizierten durch Expression von Membran-verankerten gp41-Peptiden

Publications (1)

Publication Number Publication Date
ZA200204710B true ZA200204710B (en) 2003-05-15

Family

ID=7931006

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200204710A ZA200204710B (en) 1999-11-25 2002-06-12 Gene therapy of HIV-positive patients by the expression of membrane-achored GP41 peptides.

Country Status (21)

Country Link
US (1) US7790870B1 (xx)
EP (1) EP1234044B1 (xx)
JP (1) JP2003529339A (xx)
KR (1) KR100840430B1 (xx)
CN (1) CN1425072A (xx)
AT (1) ATE412757T1 (xx)
AU (1) AU3004101A (xx)
BR (1) BR0015942A (xx)
CA (1) CA2392468A1 (xx)
CZ (1) CZ20021764A3 (xx)
DE (2) DE19957838C2 (xx)
EA (1) EA006434B1 (xx)
ES (1) ES2315247T3 (xx)
HK (1) HK1049186B (xx)
HU (1) HUP0203518A2 (xx)
NO (1) NO20022468L (xx)
PL (1) PL358785A1 (xx)
SK (1) SK7132002A3 (xx)
UA (1) UA78968C2 (xx)
WO (1) WO2001037881A2 (xx)
ZA (1) ZA200204710B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10257770A1 (de) * 2002-12-10 2004-07-08 Ruprecht-Karls-Universität Heidelberg Expression von Peptiden des zytoplasmatischen Bereiches von HIV-gp41 zur Hemmung viraler Infektionen
CA2548483A1 (en) * 2003-08-26 2005-03-10 Uwe Fiebig Induction of antiviral neutralizing antibodies in humans and animals
WO2005056804A1 (ja) * 2003-12-11 2005-06-23 Takara Bio Inc. レセプターの機能の調節方法
GB0422439D0 (en) * 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
EP1843777A2 (en) * 2005-01-24 2007-10-17 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. HIV-1 gp41 FUSION PEPTIDES FOR IMMUNOMODULATION
WO2023030312A1 (zh) * 2021-08-30 2023-03-09 康霖生物科技（杭州）有限公司 一种用于艾滋病病毒感染基因治疗的基因序列构建体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
WO1996007747A1 (de) * 1994-09-08 1996-03-14 Boehringer Mannheim Gmbh Retrovirale vektorhybride und deren verwendung zum gentransfer
WO1996030523A2 (en) * 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
FR2762851B1 (fr) * 1997-04-30 1999-10-29 Inst Nat Sante Rech Med Construction et expression d'enveloppe chimerique de retrovirus par des vecteurs et compositions pharmaceutiques les contenant
AU3220500A (en) * 1999-02-02 2000-08-25 Uab Research Foundation, The Hiv drug resistance system

Also Published As

Publication number Publication date
US7790870B1 (en) 2010-09-07
KR100840430B1 (ko) 2008-06-20
DE19957838C2 (de) 2002-11-21
KR20020060752A (ko) 2002-07-18
NO20022468D0 (no) 2002-05-24
EP1234044A2 (de) 2002-08-28
HUP0203518A2 (en) 2003-02-28
DE50015431D1 (de) 2008-12-11
SK7132002A3 (en) 2002-10-08
HK1049186B (zh) 2009-02-27
WO2001037881A9 (de) 2002-11-07
EA006434B1 (ru) 2005-12-29
UA78968C2 (en) 2007-05-10
JP2003529339A (ja) 2003-10-07
EP1234044B1 (de) 2008-10-29
ATE412757T1 (de) 2008-11-15
CN1425072A (zh) 2003-06-18
WO2001037881A3 (de) 2001-12-13
ES2315247T3 (es) 2009-04-01
PL358785A1 (en) 2004-08-23
HK1049186A1 (en) 2003-05-02
NO20022468L (no) 2002-07-22
CA2392468A1 (en) 2001-05-31
CZ20021764A3 (cs) 2003-02-12
EA200200598A1 (ru) 2002-12-26
AU3004101A (en) 2001-06-04
WO2001037881A2 (de) 2001-05-31
DE19957838A1 (de) 2001-06-13
BR0015942A (pt) 2002-08-27

Similar Documents

Publication Publication Date Title
DK1171465T3 (da) Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
DE69326069D1 (de) Zusammensetzungen die die hiv replikation inhibieren
ES2192620T3 (es) Polipeptido receptor de il-13.
IL134341A0 (en) Compositions for inducing an immune response containing an hpv protein antigen
WO2007149491A3 (en) Soluble stabilized trimeric hiv env proteins and uses thereof
ATE529434T1 (de) Transfektionskomplexe
ZA200204710B (en) Gene therapy of HIV-positive patients by the expression of membrane-achored GP41 peptides.
EP1244797A4 (en) FUSION PROTEIN ADMINISTRATION SYSTEM AND ITS USES
DE60236579D1 (de) Bakteriophagenvermittelte impfung
IL117194A0 (en) Amplifying sequences vectors comprising them and their uses in compositions for the expression of nucleotide sequences and pharmaceutical compositions containing them
GB2368846B (en) Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use
PT817858E (pt) Preparacoes fotoprotectoras que compreendem derivados de triazina
DE69935599D1 (de) Modifizierte hcv peptid-impfstoffe
ATE296314T1 (de) Peptide des env-gens vom katze immunschwäche- virus und deren verwendung
NZ513549A (en) Malaria vaccine
GB0024203D0 (en) Stabilisation of plasmid inheritance in bacteria
WO2003029285A3 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections
WO2006078268A3 (en) A peptide that elicits neutralizing antibodies targeting the hiv co-receptor, ccr5
GB2336844A (en) Anti-hiv peptides and proteins
EP1557466A4 (en) TUMOR ANTIGEN PROTEIN AND USE THEREOF
NZ508812A (en) Peptides for the prevention or treatment of HIV
MXPA04004970A (es) Epitopos de linfocitos t en carboxipeptidasa g2.
GB0222824D0 (en) Bacteriophage-mediated immunisation II